Head-to-head · free
Merck vs Regeneron Pharmaceuticals, Inc.
MRK vs REGN — return on capital, cash generation, margins and balance sheet side by side.
MRK
6 / 8
measures where MRK leads
REGN
2 / 8
measures where REGN leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | MRK · FY2025 | REGN · FY2025 |
|---|---|---|
| Revenue | $65.0B | $14.3B |
| Net income | $18.3B | $4.5B |
| Revenue growth (yearly, multi-year) | 7.5% | -2.8% |
| Free cash flow | $12.4B | — |
| Free cash flow margin | 19.0% | — |
| Net cash / (debt) | — | — |
| ROIC | 19.0% | 9.3% |
| Return on equity | 36.9% | 14.9% |
| Gross margin | 74.8% | 85.4% |
| Operating margin | 34.0% | 25.8% |
| Net debt / EBITDA | 1.29x | -0.27x |
Figures are as reported by each company; latest fiscal year shown.
Where Merck's cash went (FY2025)
- Capital spending
- $4.1B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Regeneron Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free